More on ABLD
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $30.19 |
|
|||
| Open | $30.10 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $30.13 | ||||
| Day Low | $29.96 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 7,042 | ||||
- ABL Diagnostics – Approval of Dividend Distribution for Fiscal Year 2025
- ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified
- ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031
- ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France
- ABL Diagnostics: Information Relating to the Total Number of Voting Rights and the Total Number of Shares Composing the Share Capital
- ABL Diagnostics: Ordinary and Extraordinary General Meeting of June 30, 2026 – Terms for Making Available or Consulting Preparatory Documents
- ABL Diagnostics: Sale of a new block of shares by its main shareholder ABL
- ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL
- ABL Diagnostics Presents Its Financial Roadmap and Growth Outlook for 2026
- Allinvest Reiterates Its "BUY" Rating on ABL Diagnostics and Maintains a €8.4 Target Price (Representing a 2.2X Multiple)
